Cellular responses of smooth muscle cells to epigallocatechin gallate-releasing bioresorbable polymer and its cellular mechanism

H.-H CHO¹, D.-W HAN¹, K.MATSUMURA¹, N. NAKAJIMA¹, D.-Y JUNG², S. TSUTSUMI¹, S.-H HYON^{1,*}

1. Research Center for Nano Medical Engineering, Institute for Frontier Medical Sciences, Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan 2. Division of Medical Devices, National Institute of Health Sciences, Kamiyoga 1-18-1, Setagaya-ku, Tokyo 158-8501, Japan.

Introduction: A major complication of coronary stenting is restenosis, often accompanied by inflammatory reactions and smooth muscle cell proliferation and migration. (-)epigallocatechin-3-O-gallate (EGCG), a major polyphenolic constituent of green tea, has been shown to exert antithrombotic, anti-inflammatory and anti-proliferative activities [1,2]. In this study, it was hypothesized that the sustained release of EGCG from bioresorbable poly (lactic acid-co- ε -caprolactone, PLCL) would proliferation and migration of vascular smooth muscle cells (VSMCs), and nuclear factor-κB (NF-κB) might be involved as a mechanism of this reduction by EGCG.

Materials & Methods:

Preparation of EGCG-releasing PLCL (E-PLCL) copolymer films: Bioresorbable, non-porous PLCL (75:25=mol/mol, MW 130,000 ~ 160,000) thin films (9 mm in diameter and 0.1 mm in thickness) used in this study were kindly supplied from BMG Inc. (Kyoto, Japan). E-PLCL copolymers were fabricated by mixing PLCL with 5 and 10 wt% EGCG (TEAVIGOTM, DSM Nutritional Products) in acetone at 60°C.

Primary culture of vascular smooth muscle cells from rat aorta: VSMCs were obtained by limited enzymatic digestion from the tunica media of rat thoracic aorta as previously reported (3).

EGCG release from E-PLCL copolymer: E-PLCL films were attached to the bottom of a glass vial by using vacuum grease and then incubated in phosphate-buffered saline (PBS, pH 7.4) at 37°C for 15 days. At the end of each predetermined incubation period, the concentration of EGCG released from the copolymer in media was quantified by absorbance at 275 nm in a UV spectrophotometer.

Cell attachment and proliferation assays: VSMCs were seeded onto intact PLCL and E-PLCL films at a seeding density of 1×10⁴cells/cm². Cell attachment at 6h and cell proliferation at 1 and 3 days were determined by WST method. VSMC attachment and proliferation were found to be directly proportional to the metabolic reaction products obtained in water soluble tetrazolium salt (WST-8, Dojindo Lab., Kumamoto, Japan). The absorbance was determined at 450 nm in a microplate reader. In addition, proliferated cell morphologies were observed after 3days by a immunocyotochemical analysis.

Cell migration assay: VSMCs were seeded onto 48-well plates at density of 2×10^4 cells/well and then grown to confluence. Monolayers were scraped (denuded) using a 1 ml plastic micropipette tip, and replaced with or without conditioned media obtained by incubating E-PLCL in the fresh media. The cells were incubated and

then visualized for the cells that migrated toward denuded space for 72 h by immunocytochemical analysis.

Results & Discussion:




Figure 3. Migration of VSMCs onto intact and E-PLCL films at 3 days after cell scratch.

As shown in figure 1, EGCG was sustainedly released from E-PLCL. The proliferation of VSMCs onto E-PLCL was significantly inhibited in spite of serum stimulation (figure2). Recovery of denuded area by VSMCs receiving conditioned media obtained from 10%E-PLCL was significantly inhibited after 72 h, whereas VSMCs without conditioned media migrated into denuded area showing complete recovery onto intact PLCL (figure 3). In VSMCs cultured onto E-PLCL, furthermore, the expression of NF- κ B completely disappeared. These results suggest that the inhibitory effect of EGCG released from bioresorbable polymers on VSMC behaviors may be mediated through NF- κ B suppression, and these EGCG-releasing polymers can be applied for fabricating an EGCG-eluting vascular stent.

References:

- 1. Kang WS et al. Thromb Res 1999;96(3):229-237
- 2. Maeda K et al. Atherosclerosis 2003;166(1):23-30
- 3. Hwang KC et al. J. Cardiovasc. Pharmacol. 2002;39: 271-277.